Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Syndicate
TCR2 Therapeutics 8M share Secondary priced at $15.50 » 20:11
07/28/20
07/28
20:11
07/28/20
20:11
TCRR

TCR2 Therapeutics

$16.28 /

-0.11 (-0.67%)

The deal size was…

The deal size was increased to 8M shares from 6M shares and priced below the last closing price of $16.28. Jefferies, SVB Leerink, Piper Sandler and BMO Capital are acting as joint book running managers for the offering.

ShowHide Related Items >><<
TCRR TCR2 Therapeutics
$16.28 /

-0.11 (-0.67%)

TCRR TCR2 Therapeutics
$16.28 /

-0.11 (-0.67%)

07/27/20 H.C. Wainwright
TCR2 Therapeutics price target raised to $33 from $19 at H.C. Wainwright
07/27/20 Roth Capital
TCR2 Therapeutics upgraded to Buy from Neutral at Roth Capital
07/27/20 Wedbush
TCR2 Therapeutics price target raised to $32 from $25 at Wedbush
11/04/19 H.C. Wainwright
TCR2 Therapeutics initiated with a Buy at H.C. Wainwright
TCRR TCR2 Therapeutics
$16.28 /

-0.11 (-0.67%)

  • 29
    Jul
Syndicate
TCR2 Therapeutics announces offering of 6M shares of common stock » 16:02
07/27/20
07/27
16:02
07/27/20
16:02
TCRR

TCR2 Therapeutics

$16.07 /

+3.03 (+23.24%)

TCR2 Therapeutics…

TCR2 Therapeutics announced that it has commenced an underwritten public offering of 6M shares of its common stock. TCR2 intends to use the net proceeds of the offering to advance its clinical and earlier stage programs and for research and development, working capital and general corporate purposes. Jefferies, SVB Leerink, Piper Sandler and BMO Capital Markets are acting as joint book-running managers for the offering. SunTrust Robinson Humphrey is acting as co-manager for the offering.

ShowHide Related Items >><<
TCRR TCR2 Therapeutics
$16.07 /

+3.03 (+23.24%)

TCRR TCR2 Therapeutics
$16.07 /

+3.03 (+23.24%)

07/27/20 H.C. Wainwright
TCR2 Therapeutics price target raised to $33 from $19 at H.C. Wainwright
07/27/20 Roth Capital
TCR2 Therapeutics upgraded to Buy from Neutral at Roth Capital
07/27/20 Wedbush
TCR2 Therapeutics price target raised to $32 from $25 at Wedbush
11/04/19 H.C. Wainwright
TCR2 Therapeutics initiated with a Buy at H.C. Wainwright
TCRR TCR2 Therapeutics
$16.07 /

+3.03 (+23.24%)

Recommendations
TCR2 Therapeutics price target raised to $33 from $19 at H.C. Wainwright » 10:47
07/27/20
07/27
10:47
07/27/20
10:47
TCRR

TCR2 Therapeutics

$17.09 /

+4.05 (+31.06%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Raghuram Selvaraju raised the firm's price target on TCR2 Therapeutics to $33 from $19 and keeps a Buy rating on the shares after the company reported interim Phase 1 data for TC-210 in mesothelin-expressing solid tumors that the analyst called "encouraging." Given the encouraging early efficacy signal, Selvaraju increased the probability of approval for TC-210 in mesothelioma to 35% from 20% and to 20% from 10% in cholangiocarcinoma, ovarian cancer, and NSCLC, the analyst tells investors.

ShowHide Related Items >><<
TCRR TCR2 Therapeutics
$17.09 /

+4.05 (+31.06%)

TCRR TCR2 Therapeutics
$17.09 /

+4.05 (+31.06%)

07/27/20 Roth Capital
TCR2 Therapeutics upgraded to Buy from Neutral at Roth Capital
07/27/20 Wedbush
TCR2 Therapeutics price target raised to $32 from $25 at Wedbush
11/04/19 H.C. Wainwright
TCR2 Therapeutics initiated with a Buy at H.C. Wainwright
TCRR TCR2 Therapeutics
$17.09 /

+4.05 (+31.06%)

Upgrade
TCR2 Therapeutics upgraded to Buy from Neutral at Roth Capital » 08:20
07/27/20
07/27
08:20
07/27/20
08:20
TCRR

TCR2 Therapeutics

$13.04 /

-0.56 (-4.12%)

Roth Capital analyst Tony…

Roth Capital analyst Tony Butler upgraded TCR2 Therapeutics to Buy from Neutral with a price target of $35, up from $16. The analyst notes that TCR2 presented the first human data from its mesothelin-directed "TRuC" T-cells, TC-210, in solid tumors. Despite positive pre-clinical evidence of greater anti-tumor activity, it was unclear if TRuC-T cells would behave similarly in humans with solid tumors, he contends.

ShowHide Related Items >><<
TCRR TCR2 Therapeutics
$13.04 /

-0.56 (-4.12%)

TCRR TCR2 Therapeutics
$13.04 /

-0.56 (-4.12%)

07/27/20 Wedbush
TCR2 Therapeutics price target raised to $32 from $25 at Wedbush
11/04/19 H.C. Wainwright
TCR2 Therapeutics initiated with a Buy at H.C. Wainwright
TCRR TCR2 Therapeutics
$13.04 /

-0.56 (-4.12%)

Recommendations
TCR2 Therapeutics price target raised to $32 from $25 at Wedbush » 07:45
07/27/20
07/27
07:45
07/27/20
07:45
TCRR

TCR2 Therapeutics

$13.04 /

-0.56 (-4.12%)

Wedbush analyst David…

Wedbush analyst David Nierengarten raised the firm's price target on TCR2 Therapeutics to $32 from $25 following initial Phase 1 data for its lead candidate TC-210, a mesothelin-directed TRuC-T cell, being evaluated in patients with MSLN-positive, advanced solid tumors. The analyst is also lowering his risk-adjusted discount rate for TC-210 to 40% from 45% across all valued indications to reflect the "encouraging" initial TC-210 data. Nierengarten keeps an Outperform rating on the shares.

ShowHide Related Items >><<
TCRR TCR2 Therapeutics
$13.04 /

-0.56 (-4.12%)

TCRR TCR2 Therapeutics
$13.04 /

-0.56 (-4.12%)

11/04/19 H.C. Wainwright
TCR2 Therapeutics initiated with a Buy at H.C. Wainwright
TCRR TCR2 Therapeutics
$13.04 /

-0.56 (-4.12%)

Hot Stocks
TCR2 Therapeutics announces interim data for Phase 1 of TC-210 trial » 17:28
07/26/20
07/26
17:28
07/26/20
17:28
TCRR

TCR2 Therapeutics

$13.04 /

-0.56 (-4.12%)

TCR2 Therapeutics…

TCR2 Therapeutics announced interim data from the first five patients treated in the Phase 1 portion of the TC-210 Phase 1/2 clinical trial for mesothelin-expressing solid tumors. All five patients showed tumor regression including two RECIST unconfirmed partial responses - one of which remains subject to independent central review - and two patients with stable disease through six months. Translational data further demonstrated TRuC-T cell expansion and activation. A manageable toxicity profile was observed with only one patient exhibiting TC-210-related non-hematologic grade greater than 2 toxicity and no evidence of neurotoxicity or on-target, off-tumor toxicity. The primary objectives of the Phase 1 portion of the study are to define the safety profile of TC-210 in patients whose tumors overexpress mesothelin and to determine the recommended Phase 2 dose. Secondary objectives include overall response rate and disease control rate. Exploratory objectives include the assessment of expansion, tumor infiltration, and persistence of TC-210 T cells. TC-210 was generally well tolerated, with no patients experiencing neurotoxicity or on-target, off-tumor toxicities. Three patients experienced Cytokine Release Syndrome, which was Grade 1 in two patients and Grade 3 in one patient. The patient experiencing Grade 3 CRS also developed Grade 3 pneumonitis during the first week post infusion that responded to tocilizumab and steroid therapy. This patient died 34 days post treatment due to fungal sepsis, which was deemed unrelated to TC-210. Because of the earlier pneumonitis event, however, the Safety Review Team recommended the expansion of the cohort from three to six patients. None of the subsequent three patients treated at DL1 developed pneumonitis or CRS above Grade 1. All five patients treated with TC-210 T cells have had at least one disease response assessment. The DCR was 100%, with all patients experiencing tumor regression. The median change in the sum of diameters of target lesions was -42%. The ORR was 40% according to RECIST v1.1. TC-210 therapy induced a significant reduction in FDG uptake by PET imaging in two evaluable patients, including one patient who achieved a complete metabolic response. The Phase 1/2 clinical trial is evaluating the safety and efficacy of TC-210, TCR2's T-cell receptor fusion construct directed against mesothelin. The trial is enrolling patients with mesothelin expressing NSCLC, ovarian cancer, cholangiocarcinoma, and malignant pleural/peritoneal mesothelioma. The Phase 1 dose escalation portion of the clinical trial utilizes a modified 3+3 design with four increasing TC-210 T cell doses. At each dose, TC-210 will be tested in two separate dose levels: first without lymphodepletion and then following lymphodepleting chemotherapy. The Phase 1 portion of the clinical trial is ongoing. In the Phase 2 portion of the clinical trial, approximately 50 patients are planned to receive TC-210 at the RP2D in four distinct cohorts according to their cancer diagnosis: NSCLC, ovarian cancer, malignant pleural/peritoneal mesothelioma and cholangiocarcinoma. Each cohort will include ten patients, except the NSCLC cohort which will include 20 patients with eight patients to receive TC-210 as single agent and 12 patients to receive TC-210 in combination with a programmed cell death 1 blocking antibody.

ShowHide Related Items >><<
TCRR TCR2 Therapeutics
$13.04 /

-0.56 (-4.12%)

TCRR TCR2 Therapeutics
$13.04 /

-0.56 (-4.12%)

11/04/19 H.C. Wainwright
TCR2 Therapeutics initiated with a Buy at H.C. Wainwright
TCRR TCR2 Therapeutics
$13.04 /

-0.56 (-4.12%)

Over a month ago
Hot Stocks
TCR2 Therapeutics appoints Gregg McConnell as head of business development » 08:11
05/27/20
05/27
08:11
05/27/20
08:11
TCRR

TCR2 Therapeutics

$11.70 /

+0.66 (+5.98%)

, BMY

Bristol-Myers

$60.33 /

-0.45 (-0.74%)

TCR2 Therapeutics (TCRR)…

TCR2 Therapeutics (TCRR) announced an expansion of its leadership team to strengthen expertise in business development and regulatory affairs as the Company advances the development of TRuC-T cells addressing solid tumors and hematological malignancies. Gregg McConnell joins TCR2 as Head of Business Development. Most recently, he served as Vice President and Head of Business Development at BlueRock Therapeutics. Viera Muzithras joins TCR2 as VP of Regulatory Affairs. With over 25 years of global regulatory experience focusing on cell and gene therapy, oncology and vaccines, she most recently served as Executive Director of Global Regulatory Affairs at Bristol Myers Squibb (BMY).

ShowHide Related Items >><<
BMY Bristol-Myers
$60.33 /

-0.45 (-0.74%)

TCRR TCR2 Therapeutics
$11.70 /

+0.66 (+5.98%)

11/04/19 H.C. Wainwright
TCR2 Therapeutics initiated with a Buy at H.C. Wainwright
05/31/19 Roth Capital
TCR2 Therapeutics initiated with a Neutral at Roth Capital
BMY Bristol-Myers
$60.33 /

-0.45 (-0.74%)

05/13/20 Stifel
Bluebird's ide-cel remains approvable despite FDA's 'strict stance,' says Stifel
05/13/20 Piper Sandler
Bluebird should be able to easily address RTF issues, says Piper Sandler
05/12/20 Oppenheimer
Bluebird Bio price target lowered to $111 from $122 at Oppenheimer
04/20/20 Piper Sandler
Exelixis combo approval would increase kidney cancer use, says Piper Sandler
TCRR TCR2 Therapeutics
$11.70 /

+0.66 (+5.98%)

BMY Bristol-Myers
$60.33 /

-0.45 (-0.74%)

BMY Bristol-Myers
$60.33 /

-0.45 (-0.74%)

BMY Bristol-Myers
$60.33 /

-0.45 (-0.74%)

BMY Bristol-Myers
$60.33 /

-0.45 (-0.74%)

Earnings
TCR2 Therapeutics reports Q1 EPS (65c), consensus (60c) » 06:55
05/14/20
05/14
06:55
05/14/20
06:55
TCRR

TCR2 Therapeutics

$9.58 /

-0.95 (-9.02%)

TCR2 ended Q1 with…

TCR2 ended Q1 with $140.7M in cash, cash equivalents, and investments vs. $158.1M as of December 31, 2019. Q1 net cash used in operations was $16.4M vs. $10.8M for 1Q19. TCR2 projects net cash use of $60M-$70M for 2020. While the company believes it has been able, to date, to mitigate some of the impact from the COVID-19 pandemic on its ongoing clinical programs, it is committed to providing an interim update of the Phase 1 portion of the TC-210 Phase 1/2 clinical trial in mid-2020 and the Phase 1 portion of the TC-110 Phase 1/2 clinical trial in the second half of 2020. "Based on our clinical progress to date and a growing confidence in our TRuC platform, we are advancing a third mono TRuC-T cell candidate targeting CD70, a clinically validated target which will allow us to make further inroads into both solid tumors and hematological malignancies," said CEO Garry Menzel. "In addition, the expression of CD70 in tumors where CD19 and mesothelin are overexpressed represents a good opportunity for our dual TRuCs. With this new program and the strengthening of our Board with the appointments of Axel Hoos and Stephen Webster, we are well-positioned to deliver on the near- and long-term value opportunities of our platform as we approach data for our lead assets in 2020."

ShowHide Related Items >><<
TCRR TCR2 Therapeutics
$9.58 /

-0.95 (-9.02%)

11/04/19 H.C. Wainwright
TCR2 Therapeutics initiated with a Buy at H.C. Wainwright
05/31/19 Roth Capital
TCR2 Therapeutics initiated with a Neutral at Roth Capital
TCRR TCR2 Therapeutics
$9.58 /

-0.95 (-9.02%)

Over a quarter ago
Conference/Events
Roth Capital biotech analysts to hold an analyst/industry conference call » 09:25
04/30/20
04/30
09:25
04/30/20
09:25
ADAP

Adaptimmune

$3.83 /

+0.315 (+8.96%)

, ALLO

Allogene Therapeutics

$28.15 /

+1.54 (+5.79%)

, ARVN

Arvinas

$53.85 /

+0.58 (+1.09%)

, BCYC

Bicycle Therapeutics

$13.11 /

-1.6 (-10.88%)

, CGEN

Compugen

$15.03 /

+1.26 (+9.15%)

, CRVS

Corvus Pharmaceuticals

$2.58 /

+ (+0.00%)

, FPRX

Five Prime

$3.34 /

+0.26 (+8.44%)

, HARP

Harpoon Therapeutics

$13.27 /

+0.12 (+0.91%)

, MRUS

Merus

$16.03 /

+1.225 (+8.28%)

, NXTC

NextCure

$36.52 /

+1.42 (+4.05%)

, REPL

Replimune Group

$15.00 /

+2.29 (+18.02%)

, TCRR

TCR2 Therapeutics

$11.45 /

+0.43 (+3.90%)

Biotech Analysts Butler…

Biotech Analysts Butler and Jallah review the companies and the abstract titles to be presented at the upcoming ASCO Virtual Meeting (May 29-31) on an Analyst/Industry conference call to be held on April 30 at 10 am.

ShowHide Related Items >><<
ADAP Adaptimmune
$3.83 /

+0.315 (+8.96%)

04/21/20 Mizuho
Adaptimmune initiated with a Neutral at Mizuho
10/23/19
Adaptimmune management to meet with SunTrust
08/02/19
Fly Intel: Top five analyst downgrades
08/02/19 Guggenheim
Adaptimmune downgraded to Neutral on low near-term visibility at Guggenheim
ALLO Allogene Therapeutics
$28.15 /

+1.54 (+5.79%)

04/13/20
Fly Intel: Top five analyst initiations
04/13/20 Truist
Allogene Therapeutics initiated with a Buy at SunTrust
04/13/20 Truist
Allogene Therapeutics initiated with a Buy at SunTrust
03/27/20 Roth Capital
Allogene seeing ALL trial disruption from COVID-19, says Roth Capital
ARVN Arvinas
$53.85 /

+0.58 (+1.09%)

04/29/20 H.C. Wainwright
Arvinas price target raised to $60 from $50 at H.C. Wainwright
04/21/20 Cantor Fitzgerald
Arvinas could have 'major' year in 2020, says Cantor Fitzgerald
04/14/20 Cantor Fitzgerald
Arvinas a top pick, COVID-19 impacts unsurprising, says Cantor Fitzgerald
03/25/20 Wedbush
Arvinas added to Best Ideas List at Wedbush
BCYC Bicycle Therapeutics
$13.11 /

-1.6 (-10.88%)

04/17/20
Fly Intel: Top five analyst initiations
04/17/20 H.C. Wainwright
Bicycle Therapeutics initiated with a Buy at H.C. Wainwright
04/07/20 Piper Sandler
Bicycle Therapeutics' timelines to be impacted by COVID-19, says Piper Sandler
02/25/20 Piper Sandler
Bicycle Therapeutics price target raised to $30 from $20 at Piper Sandler
CGEN Compugen
$15.03 /

+1.26 (+9.15%)

04/28/20 Truist
Compugen price target raised to $22 from $16 at SunTrust
04/22/20 Roth Capital
Compugen initiated with a Buy at Roth Capital
03/24/20
Fly Intel: Top five analyst initiations
03/24/20 Truist
Compugen initiated with a Buy at SunTrust
CRVS Corvus Pharmaceuticals
$2.58 /

+ (+0.00%)

03/10/20 H.C. Wainwright
Corvus Pharmaceuticals initiated with a Buy at H.C. Wainwright
12/09/19 Mizuho
Corvus pipeline updates 'can only be additive,' says Mizuho
09/12/19 Mizuho
Mizuho starts Corvus Pharmaceuticals with Buy rating, $7 price target
09/11/19 Mizuho
Corvus Pharmaceuticals initiated with a Buy at Mizuho
FPRX Five Prime
$3.34 /

+0.26 (+8.44%)

02/28/20 JPMorgan
Five Prime downgraded to Underweight from Neutral at JPMorgan
02/28/20 JPMorgan
Five Prime downgraded to Underweight from Neutral at JPMorgan
02/19/20 Wedbush
Five Prime downgraded to Neutral at Wedbush as cabiralizumab study flops
02/18/20 Wedbush
Five Prime downgraded to Neutral from Outperform at Wedbush
HARP Harpoon Therapeutics
$13.27 /

+0.12 (+0.91%)

04/16/20 Citi
Citi opens 'positive 90-day catalyst watch' on Harpoon Therapeutics
02/28/20
Fly Intel: Top five analyst initiations
02/27/20 Truist
Harpoon Therapeutics initiated with a Buy at SunTrust
02/03/20
Fly Intel: Top five analyst initiations
MRUS Merus
$16.03 /

+1.225 (+8.28%)

11/20/19 Guggenheim
Merus assumed with a Buy at Guggenheim
06/28/19 Roth Capital
Merus initiated with a Buy at Roth Capital
NXTC NextCure
$36.52 /

+1.42 (+4.05%)

04/13/20 Piper Sandler
NextCure could report Phase I biomarker data at ASCO, says Piper Sandler
03/24/20 Benchmark
NextCure initiated with a Buy at Benchmark
03/02/20 Roth Capital
NextCure initiated with a Buy at Roth Capital
01/13/20 Piper Sandler
Partnership termination not a negative for NextCure N318, says Piper Sandler
REPL Replimune Group
$15.00 /

+2.29 (+18.02%)

03/25/20 Wedbush
Replimune Group added to Best Ideas List at Wedbush
11/11/19 Roth Capital
Replimune Group price target raised to $30 from $20 at Roth Capital
09/04/19 Roth Capital
Replimune Group initiated with a Buy at Roth Capital
08/06/19 Wedbush
Replimune Group, Sallie Mae removed from Best Ideas List at Wedbush
TCRR TCR2 Therapeutics
$11.45 /

+0.43 (+3.90%)

11/04/19 H.C. Wainwright
TCR2 Therapeutics initiated with a Buy at H.C. Wainwright
05/31/19 Roth Capital
TCR2 Therapeutics initiated with a Neutral at Roth Capital
Conference/Events
Roth Capital biotech analysts to hold an analyst/industry conference call » 04:55
04/30/20
04/30
04:55
04/30/20
04:55
ADAP

Adaptimmune

$3.83 /

+0.315 (+8.96%)

, ALLO

Allogene Therapeutics

$28.15 /

+1.54 (+5.79%)

, ARVN

Arvinas

$53.85 /

+0.58 (+1.09%)

, BCYC

Bicycle Therapeutics

$13.11 /

-1.6 (-10.88%)

, CGEN

Compugen

$15.03 /

+1.26 (+9.15%)

, CRVS

Corvus Pharmaceuticals

$2.58 /

+ (+0.00%)

, FPRX

Five Prime

$3.34 /

+0.26 (+8.44%)

, HARP

Harpoon Therapeutics

$13.27 /

+0.12 (+0.91%)

, MRUS

Merus

$16.03 /

+1.225 (+8.28%)

, NXTC

NextCure

$36.52 /

+1.42 (+4.05%)

, REPL

Replimune Group

$15.00 /

+2.29 (+18.02%)

, TCRR

TCR2 Therapeutics

$11.45 /

+0.43 (+3.90%)

Biotech Analysts Butler…

Biotech Analysts Butler and Jallah review the companies and the abstract titles to be presented at the upcoming ASCO Virtual Meeting (May 29-31) on an Analyst/Industry conference call to be held on April 30 at 10 am.

ShowHide Related Items >><<
ADAP Adaptimmune
$3.83 /

+0.315 (+8.96%)

04/21/20 Mizuho
Adaptimmune initiated with a Neutral at Mizuho
10/23/19
Adaptimmune management to meet with SunTrust
08/02/19
Fly Intel: Top five analyst downgrades
08/02/19 Guggenheim
Adaptimmune downgraded to Neutral on low near-term visibility at Guggenheim
ALLO Allogene Therapeutics
$28.15 /

+1.54 (+5.79%)

04/13/20
Fly Intel: Top five analyst initiations
04/13/20 Truist
Allogene Therapeutics initiated with a Buy at SunTrust
04/13/20 Truist
Allogene Therapeutics initiated with a Buy at SunTrust
03/27/20 Roth Capital
Allogene seeing ALL trial disruption from COVID-19, says Roth Capital
ARVN Arvinas
$53.85 /

+0.58 (+1.09%)

04/29/20 H.C. Wainwright
Arvinas price target raised to $60 from $50 at H.C. Wainwright
04/21/20 Cantor Fitzgerald
Arvinas could have 'major' year in 2020, says Cantor Fitzgerald
04/14/20 Cantor Fitzgerald
Arvinas a top pick, COVID-19 impacts unsurprising, says Cantor Fitzgerald
03/25/20 Wedbush
Arvinas added to Best Ideas List at Wedbush
BCYC Bicycle Therapeutics
$13.11 /

-1.6 (-10.88%)

04/17/20
Fly Intel: Top five analyst initiations
04/17/20 H.C. Wainwright
Bicycle Therapeutics initiated with a Buy at H.C. Wainwright
04/07/20 Piper Sandler
Bicycle Therapeutics' timelines to be impacted by COVID-19, says Piper Sandler
02/25/20 Piper Sandler
Bicycle Therapeutics price target raised to $30 from $20 at Piper Sandler
CGEN Compugen
$15.03 /

+1.26 (+9.15%)

04/28/20 Truist
Compugen price target raised to $22 from $16 at SunTrust
04/22/20 Roth Capital
Compugen initiated with a Buy at Roth Capital
03/24/20
Fly Intel: Top five analyst initiations
03/24/20 Truist
Compugen initiated with a Buy at SunTrust
CRVS Corvus Pharmaceuticals
$2.58 /

+ (+0.00%)

03/10/20 H.C. Wainwright
Corvus Pharmaceuticals initiated with a Buy at H.C. Wainwright
12/09/19 Mizuho
Corvus pipeline updates 'can only be additive,' says Mizuho
09/12/19 Mizuho
Mizuho starts Corvus Pharmaceuticals with Buy rating, $7 price target
09/11/19 Mizuho
Corvus Pharmaceuticals initiated with a Buy at Mizuho
FPRX Five Prime
$3.34 /

+0.26 (+8.44%)

02/28/20 JPMorgan
Five Prime downgraded to Underweight from Neutral at JPMorgan
02/28/20 JPMorgan
Five Prime downgraded to Underweight from Neutral at JPMorgan
02/19/20 Wedbush
Five Prime downgraded to Neutral at Wedbush as cabiralizumab study flops
02/18/20 Wedbush
Five Prime downgraded to Neutral from Outperform at Wedbush
HARP Harpoon Therapeutics
$13.27 /

+0.12 (+0.91%)

04/16/20 Citi
Citi opens 'positive 90-day catalyst watch' on Harpoon Therapeutics
02/28/20
Fly Intel: Top five analyst initiations
02/27/20 Truist
Harpoon Therapeutics initiated with a Buy at SunTrust
02/03/20
Fly Intel: Top five analyst initiations
MRUS Merus
$16.03 /

+1.225 (+8.28%)

11/20/19 Guggenheim
Merus assumed with a Buy at Guggenheim
06/28/19 Roth Capital
Merus initiated with a Buy at Roth Capital
NXTC NextCure
$36.52 /

+1.42 (+4.05%)

04/13/20 Piper Sandler
NextCure could report Phase I biomarker data at ASCO, says Piper Sandler
03/24/20 Benchmark
NextCure initiated with a Buy at Benchmark
03/02/20 Roth Capital
NextCure initiated with a Buy at Roth Capital
01/13/20 Piper Sandler
Partnership termination not a negative for NextCure N318, says Piper Sandler
REPL Replimune Group
$15.00 /

+2.29 (+18.02%)

03/25/20 Wedbush
Replimune Group added to Best Ideas List at Wedbush
11/11/19 Roth Capital
Replimune Group price target raised to $30 from $20 at Roth Capital
09/04/19 Roth Capital
Replimune Group initiated with a Buy at Roth Capital
08/06/19 Wedbush
Replimune Group, Sallie Mae removed from Best Ideas List at Wedbush
TCRR TCR2 Therapeutics
$11.45 /

+0.43 (+3.90%)

11/04/19 H.C. Wainwright
TCR2 Therapeutics initiated with a Buy at H.C. Wainwright
05/31/19 Roth Capital
TCR2 Therapeutics initiated with a Neutral at Roth Capital

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.